Abstract HIV infection leads to age-related conditions in relatively young persons. HIV-associated neurocognitive disorders (HAND) are considered among the most prevalent of these conditions. To study the mechanisms underlying this disorder, researchers need an accurate method for measuring biological aging. Here, we apply a recently developed measure of biological aging, based on DNA methylation, to the study of biological aging in HIV+ brains. Retrospective analysis of tissue bank specimens and pre-mortem data was carried out. Fifty-eight HIV+ adults underwent a medical and neurocognitive evaluation within 1 year of death. DNA was obtained from occipital cortex and analyzed with the Illumina Infinium Human Methylation 450K platform. Biological age determined via the epigenetic clock was contrasted with chronological age to obtain a measure of age acceleration, which was then compared between those with HAND and neurocognitively normal individuals. The HAND and neurocognitively normal groups did not differ with regard to demographic, histologic, neuropathologic, or virologic variables. HAND was associated with accelerated aging relative to neurocognitively normal individuals, with average relative acceleration of 3.5 years. Age acceleration did not correlate with pre-mortem neurocognitive functioning or HAND severity. This is the first study to demonstrate that the epigenetic age of occipital cortex samples is associated with HAND status in HIV+ individuals pre-mortem. While these results suggest that the increased risk of a neurocognitive disorder due to HIV might be mediated by an epigenetic aging mechanism, future studies will be needed to validate the findings and dissect causal relationships and downstream effects.
Introduction
Although antiretroviral therapy for HIV infection is highly effective at preventing AIDS-related complications, treated patients are at a significant risk for a number of diseases typically associated with aging, including cardiovascular disease, osteoporosis, cancer, cognitive impairment, and frailty (Deeks 2011; Desquilbet et al. 2011; Fausto et al. 2006; Grinspoon and Carr 2005; Kirk et al. 2013; Lucas et al. 2007; Martin and Volberding 2010; Silverberg et al. 2009; Silverberg et al. 2011; Thomas and Doherty 2003; Triant et al. 2007; Wendelken and Valcour 2012; Womack et al. 2011) . Among the aging HIV+ population, it has become evident that the incidence of HIV-associated non-AIDS (HANA) conditions is increasing (Greene 2013) . HANA conditions affect virtually every organ system and have, as a common theme, an association with advancing age and a pathogenesis likely based on chronic inflammation. Arguably, the most prevalent HANA condition is HIV-associated neurocognitive disorder (HAND), a spectrum syndrome characterized clinically by neurocognitive impairment and biologically by chronic immune activation, oxidative stress, and excitotoxicity (Gannon et al. 2011; Kraft-Terry et al. 2009 ). Early studies indicated that older individuals were at an increased risk for HAND (Cherner et al. 2004) . Additional evidence that HAND is due, at least partially, to accelerated aging, includes studies of CSF metabolomics (Cassol et al. 2014) . in vitro analysis in astrocytes (Ojeda et al. 2014) . and neurophysiological studies (Chang et al. 2013; Holt et al. 2012) . Still, in clinical samples, telomere length has not been consistently associated with neurocognitive impairment or other indicators of neuroHIV (Giesbrecht et al. 2014; Malan-Muller et al. 2013) . Clinico-pathological studies have found age-related pathology in relatively young HIV+ cases, including reduced β-amyloid (Aβ)-42 levels in the cerebral spinal fluid (Brew et al. 2005 ) and increased Aβ deposits in brain tissue sections (Soontornniyomkij et al. 2012a) .
In order to effectively investigate accelerated aging in HIV, an accurate method for quantifying biological age is needed. Telomere length, which relates to cellular senescence, has been the most popular method for studying biological aging. An alternative and remarkably more accurate method is enabled by the epigenetic process of DNA methylation (DNAm). DNAm is probably the most widely studied epigenetic mechanism, and is a chemical process by which methyl groups are added to the DNA molecule. Methylation sometimes modifies the function of the DNA, e.g., by suppressing gene transcription. While it is well-known that DNAm is essential for normal development, a large body of literature demonstrates that it also plays an important role in aging (Jung and Pfeifer 2015; Yuan et al. 2015) . DNAm levels are particularly promising biomarkers of aging since chronological age (i.e., the calendar years that have passed since birth) has a profound effect on DNAm levels in most human tissues and cell types (Alisch et al. 2012; Bell et al. 2012; Bollati et al. 2009; Christensen et al. 2009; Day et al. 2013; Hernandez et al. 2011; Horvath et al. 2012; Johansson et al. 2013; Numata et al. 2012; Rakyan et al. 2010; Teschendorff et al. 2010) . Several recent studies support measuring accelerated aging effects using DNAm levels (Bocklandt et al. 2011; Hannum et al. 2013; Horvath 2013a) . The recently developed biomarker of aging (referred to as the epigenetic clock (Horvath 2013a) . is an attractive biomarker of aging for the following reasons: (a) it is more highly correlated with chronological age than previous biomarkers (Boks et al. 2009; Horvath et al. 2014) . (b) it applies to most tissues, cell types, and fluids that contain human DNA (with the exception of sperm), and (c) it relates, to some extent, to biological age since the DNAm age of blood is predictive of all-cause mortality even after adjusting for chronological age and a variety of known risk factors (Marioni et al. 2015a) . Similarly, markers of physical and mental fitness are also found to be associated with the epigenetic age of blood (lower abilities associated with age acceleration) (Marioni et al. 2015b) .
We recently found evidence that HIV infection is associated with accelerated epigenetic aging in both brain and peripheral blood mononuclear cells (Horvath and Levine 2015) . Specifically, the brains of those infected with HIV demonstrated age acceleration of 7.4 years compared to uninfected controls, and 5.2 years in peripheral blood mononuclear cells. While our previous article shows that HIV infected (HIV+) individuals have an accelerated aging in brain tissue, it remains to be seen if this is clinically relevant. In the current article, we test the hypothesis that individuals with HAND exhibit accelerated epigenetic aging. Toward this end, we measured the DNAm age acceleration using the epigenetic clock in post-mortem brain tissue of HIV+ individuals who were characterized pre-mortem with regards t o neurocognitive, medical, and virologic variables.
Methods Participants
This study was conducted in accordance with the University of California, Los Angeles Medical Institutional Review Board. Data and biological samples from 58 individuals enrolled in either the National Neurological AIDS Bank (NNAB) or California NeuroAIDS Tissue Network (CNTN) were used. The NNAB and CNTN are member sites of the National NeuroAIDS Tissue Consortium (Morgello et al. 2001 ) (NNTC.org). Post-mortem findings of non-HIV-related neurological disease were exclusionary, as was the diagnosis of substance dependence within 1 year of death. Participant characteristics for this cohort are shown in Table 1 . All clinical lab work was performed by CLIA-certified clinical labs.
Clinical variables

HAND diagnosis
All cases were, within 1 year of death, diagnosed as either neurocognitively normal or with HAND per established research criteria (Antinori et al. 2007 ; BClinical confirmation of the American Academy of Neurology algorithm for HIV-1-associated cognitive/motor disorder. The Dana Consortium on Therapy for HIV Dementia and Related Cognitive Disorders^1996). This was based on either the previous 1996 American Academy of Neurology criteria if their last pre-mortem evaluation occurred prior to the publication of the newer HAND research criteria BFrascati^in 2007, or according to the Frascati criteria if after 2007. The NNAB and CNTN diagnostic criteria prior to 2007 included a Bsubsyndromic^impairment classification that is essentially identical to the asymptomatic neurocognitive impairment (ANI) according to the Frascati criteria. Because the criteria for MCMD and HAD (AAN) remained essentially identical to MND and HIV-associated dementia (HAD) (Antinori et al 2007) . we were able to group participants from both diagnostic eras. The diagnosis of HAND depends largely on neurocognitive functioning, which was determined with a comprehensive battery of validated tests described previously. Tests are grouped by neurocognitive domain (e.g., learning, memory, attention, motor), and a measure of global neurocognitive functioning is also determined based on all test scores. The influence of age acceleration on domain and global neurocognitive functioning scores were examined in exploratory analyses.
CNS penetration effectiveness (CPE)
We calculated the CPE, a score that is based on the pharmacokinetic and pharmacodynamic characteristics of antiretroviral medications (Letendre 2011) . CPE scores for the regimen reported at the time of neurocognitive testing were calculated. Higher scores indicate a regimen with increased penetration of the blood brain barrier.
HIV disease measures
Peripheral blood was drawn from living participants via venipuncture and stored in EDTA and heparinized tubes and then assayed for viral load using the Roche Amplicor Assay and by flow cytometry for CD4+ subsets. Reliable assays cannot be conducted on post-mortem subjects because venipuncture cannot be collected after the heart has ceased beating and the peripheral blood has coagulated. Several measures of virologic status were evaluated. This included CD4+ cell count and HIV plasma viral load measured at the last pre-mortem visit within 1 year of death, as well as duration of HIV infection. CSF viral load at time of death was also available for a subset of individuals. In addition, HIV DNA and RNA levels as measured in medial frontal cortex were available for a subset of participants, described next.
Brain HIV viral load (DNA & RNA)
For a subset of individuals (8 neurocognitively normal and 18 HAND), HIV DNA and RNA were quantified from the dorsolateral frontal cortex, as described previously (Gelman et al. 2013) . Briefly, HIV RNA and DNA were quantified using complementary DNA (cDNA) and total genomic DNA using HIV gag/pol primer and probe sequences by PCR (Palmer et al. 2003) . The reaction contained 4 μl of cDNA or 1 μg of total DNA, 12.5 μl of Sigma JumpStart Taq ReadyMix (Cat. No. D7440, Sigma, St. Louis, MO, USA), 3.5 μl of 25 mmol/L MgCl2, 0.8 μl of 10 μmol/L HIV primer mix and 0.5 μl of 10 μmol/L HIV probe adjusted to 25 μl. Conditions were 2 min. at 95°C, 40 cycles of 15 sec. at 95°C and 60 sec. at 60°C. Real time PCR was run using an Eppendorf RealPlex (Hamburg, Germany). Copies per μg of total RNA were calculated with a standard curve using a previously quantified HIV-positive RNA primary standard (Gelman et al. 2012) .
DNA processing for methylation analysis
Tissue processing, DNA extraction, and genotyping
Frozen occipital cortex samples were shipped to the University of California Los Angeles-Biological Samples Processing Core from the NNAB and CNTN for DNA extraction. The Autopure LS nucleic acid purification instrument was used for extracting DNA. Samples were quantified using OD 260/280. Extracted DNA was then genotyped. Prior to methylation assaying, the samples were checked for concentration by Quant-iT ds DNA Assay kit (Invitrogen) and for quality by agarose gel. Medial frontal cortex was also processed for a subset of cases (two neurocognitively normal and five HAND).
DNA methylation
Methylation analysis was performed with the Illumina Infinium Human Methylation 450K BeadChip, which measures bisulfite-conversion-based, single-CpG resolution DNAm levels at 485577 CpG sites in the human genome. The standard protocol of Illumina methylation assays quantifies methylation levels by the β value using the ratio of intensities between methylated (signal A) and un-methylated (signal B) alleles. Specifically, the β value is calculated from the intensity of the methylated (M corresponding to signal A) and un-methylated (U corresponding to signal B) alleles, as the ratio of fluorescent signals β=Max(M,0)/[Max(M,0)+Max(U,0)+100]. Thus, β values range from 0 (completely un-methylated) to 1 (completely methylated) (Dunning et al. 2008 ).
The epigenetic clock
The epigenetic clock is based on the DNAm levels of 353 CpGs (Horvath 2013a) . Predicted age, referred to as DNAm age, correlates with chronological age in sorted cell types (CD4+ cells, monocytes, B cells, glial cells, neurons) and tissues and organs including whole blood, brain, breast, kidney, liver, lung, and saliva (Horvath 2013a) . By construction, the epigenetic clock (and software) applies to data generated using the Illumina 450K (Horvath 2013a) . Mathematical details and software tutorials for the epigenetic clock can be found in the additional files of (Horvath 2013a ). An online age calculator can be found at our webpage (http://labs.genetics.ucla.edu/horvath/htdocs/ dnamage/) (Horvath 2013b) . The epigenetic clock software implements a data normalization step that repurposes the Beta Mixture Quantile dilation normalization method from
Teschendorff (Teschendorff et al. 2013 ) so that it automatically references each sample to a gold standard (details can be found in Additional file 1 from (Horvath 2013a)). We defined an epigenetic measure of age acceleration by regressing DNAm age on chronological age and forming residuals. By definition, this measure of age acceleration is not correlated with chronological age. Separate measures of epigenetic age acceleration were calculated for occipital cortex and the subset of medial frontal cortex samples.
Statistical methods
Student's t tests were employed to compare the two groups (HAND vs. non-HAND) on variables that exhibited a normal distribution (e.g., various immunologic and virologic variables). In order to compare age acceleration between the two groups (e.g., HAND vs. controls), we employed the KruskalWallis test, which is a non-parametric group comparison test. Robust measures of correlation (e.g., biweight midcorrelations or Spearman's rho) were used to examine the relationship between age acceleration and ordinal variables of interest, including HCV infection, age at death, CPE score, neuropathological findings, and HIV-related measures. DNAm age acceleration residuals were calculated for each case. Separate residuals were calculated for occipital cortex and the subset of medial frontal cortex samples. This residual value was then used in statistical tests. Student's t tests were employed to compare the two groups (HAND vs. non-HAND) on demographic, immunologic, and virologic variables. In order to compare age acceleration between the two groups, we employed the Kruskal-Wallis test to compare individuals diagnosed with HAND within 1 year of death to those diagnosed as neurocognitively normal. The KruskalWallis test was also used to assess group differences in those cases where both variables showed non-normal distribution. Biweight mid-correlation or Pearson correlation were used to examine the relationship between age acceleration and other variables of interest, including HCV infection, age at death, CPE score, neurocognitive functioning, HAND severity, neuropathological findings, and HIV-related measures.
Results
Group differences are summarized in Table 1 . The two groups did not differ with regard to virologic or demographic variables, although there was a notable trend for greater duration of infection among the HAND group (p=0.056). As expected, the HAND group demonstrated a greater neurocognitive impairment (p<.001).
Epigenetic age showed greater acceleration in the HAND group, as shown by the regression lines in Fig. 1a . The overall correlation between DNAm age and chronological age was highly significant (r =0.68, p < .0001). KruskalWallis testing confirmed that individuals diagnosed with HAND within 1 year of death had greater accelerated epigenetic aging as compared to those who were diagnosed as neurocognitively normal (p = 0.032) (Fig. 1c) . As can be seen in panel A, there was an extreme outlier in the HAND group. When analyses were therefore restricted to individuals over 33 (thereby excluding this outlier and 2 other HAND cases), the correlation between DNAm age and chronological age were even stronger (r = 0.76), and the group differences more robust (p=0.027).
Correlation analysis did not reveal any significant associations between age acceleration and HCV infection (r=0.0076, p=0.95), age at the time of death (r=−0.008, p=0.94), CPE score (r = 0.06, p = 0.57), nadir CD4+ cell count (r =0.1, p=0.42), CD4+ cell count as measured at death (r=0.049, p=0.63), or plasma viral load at the time of death (r=−0.14, p=0.16). No correlation between global neurocognitive functioning (r = 0.22, p = 0.10) or HAND severity (r = 0.21, p=0.11) was observed. Further, no correlations between individual neurocognitive domains and age acceleration were observed (data not shown). Conversely, duration of HIV infection was correlated with age acceleration (r=0.28, p=0.038).
We also examined the potential confounder of comorbid neuropathological conditions. As shown in Table 2 , the HAND group had a disproportionate number of additional neuropathological findings (e.g., HIV encephalitis).
However, we found no significant correlations between age acceleration and presence or severity of these neuropathological findings.
The rate of comorbid medical conditions did not differ between those with and without HAND. Specifically, for those cases for which these data were available, we did not observe differences in incidence rates of hypertension (Χ 2 =2.6, p=0.11), hyperlipidemia (Χ 2 =2.9, p=0.09), chronic renal disease (Χ 2 =0.026, p = 0.87), diabetes, (Χ 2 = 0.363, p=0.55), viral hepatitis (Χ 2 =.077, p=0.78), end stage liver disease (Χ 2 =0.84, p=0.36), chronic obstructive pulmonary disease (Χ 2 =0.535, p=0.47), non-AIDS defining cancer and (Χ 2 = 1.13, p = 0.29), and tobacco smoking (Χ 2 = 3.71, p=0.054). Because of the trends seen for tobacco smoking and hyperlipidemia, we also compared age acceleration between those with and without these two comorbidities using the Kruskal-Wallis test. We found no significant difference tobacco users and non-users (p=0.18) or individuals with or without hyperlipidemia (p=0.81).
A small subset of cases (N=7) had DNAm age acceleration and HIV RNA and DNA derived from the medial frontal cortex. Based on this small sample, we did not observe a correlation between age acceleration and either RNA (r=−0.14, p=0.79) or DNA (r=0.14, p=0.79). There was also no association between the age acceleration in the frontal cortex and global neurocognitive functioning (r=0.22, p=0.53) or HAND severity (r=0.11, p=0.77). Because the duration of the infection was significantly correlated with age acceleration (r=0.28, p=0.038), we carried out a logistic regression analysis to determine the contribution of chronological age, duration of infection, and age acceleration to HAND status. Neither chronological age (p=0.85) nor duration of infection (p = 0.08) predicted HAND status. However, age acceleration did (p=0.04).
Finally, due to the possibility that difference in methylation were driven by difference in cellular composition (Jaffe and Irizarry 2014) . we examined the association between accelerated aging and various histopathology markers. These included human leukocyte antigen (HLA-DR-marker of macrophages), allograft inflammatory factor 1 (AIF-1-a marker of microglia), and glial fibrillary acidic protein (GFAP-a marker of astrocytes). We also examined amyloid-β deposition, as it is associated with both HIV and aging (Achim et. 2009; Green et al. 2005; Soontornniyomkij et al. 2012a ). These markers were quantified in frontal cortex, frontal white matter, hippocampus, and putamen. Histopathology and quantification procedures for these were described previously (Soontornniyomkij et al. 2010 (Soontornniyomkij et al. , 2012b Toggas and Mucke 1996) . No correlations between age acceleration and any marker in any region were observed (data not shown).
Discussion
HAND may be the most prevalent manifestation of accelerated aging due to HIV, and is among those conditions collectively referred to as HANA conditions. The biological mechanisms underlying the clinical manifestation of accelerated aging in HIV+ subjects remain elusive. We recently demonstrated accelerated aging in the brains and blood cells of HIV+ individuals. In this study, we have shown that this accelerated epigenetic aging in the post-mortem brain tissue has clinical relevance, as it is strongly associated with HAND diagnosed within 1 year of death. Based on the available data, this was not due to peripheral virologic measures (CD4+ cell count and viral load), the activity of antiretroviral medications in the CNS, or neuropathological or medical comorbidities. It is also interesting that while the HAND group as a whole exhibited accelerated aging in brain tissue, this measure was not correlated with HAND severity or neurocognitive functioning. Instead, the results implicate the duration of infection as a possible determinant of accelerated aging. These findings suggest to us that chronic, low-level HIV replication in brain reservoirs perpetuates pathological processes resulting in accelerated age as measured epigenetically; however, such changes are not reliably captured by neuropsychological instruments. As suggested in the past (e.g., . this supports the need to implement intermediate-level phenotypes (e.g., neurophysiological and histopathological) in studies of HAND pathogenesis, rather than relying solely on the neurocognitive manifestations.
Studies of dynamic cellular processes including transcription and translation have revealed potential targets for use as biomarkers or drug development in neuroHIV (Levine et al. 2013a, b; Pendyala & Fox 2010; Pulliam et al. 2011; Winkler et al. 2012) . The quantification of epigenetic processes on a whole-genome scope and the delineation of their role in disease have become increasingly feasible in recent years. In particular, DNAm has become recognized as a significant determinant in cellular processes, and one that is highly variable as a function of disease status. Despite its potential role in HAND, there are no published studies of DNAm in this context. Indeed, there are very few studies overall on epigenetics and HAND (Desplats et al. 2013; Kazantsev and Thompson 2008; Mukerjee et al. 2011; Narasipura and Al-Harthi 2014; Saiyed et al. 2011; Sun et al. 2003; Tatro et al. 2010) , as recently reviewed (Kallianpur and Levine 2014; Levine et al. 2014 ). To our knowledge there have been no peerreviewed studies examining global (i.e., genome-wide) DNAm in the context of HAND (Perez-Santiago et al. 2012 ). As such, this nascent area of investigation may indeed yield important information about the neuropathogenesis of HAND.
The results of this study should be interpreted with the following caveats. It may be that the cause of death influenced brain methylation. Unfortunately, cause of death was not collected in a consistent evaluable way in this multi-site study. Regardless, cause of death is oftentimes unreliable due to the multiple comorbidities of the participants and the fact that the condition that ultimately led to death (e.g., pneumonia) may not be related to the condition that precipitated it (e.g., hepatitis). More relevant, considering that we have examined brain DNA, are the neuropathological findings that are consistently gathered according to a standard protocol. We did not find any of the brain pathologies to be the cause of the age acceleration differences between the HAND and neurocognitively normal groups. In addition, the relationship between viral load and age acceleration was not fully addressed, as plasma virologic measures at the time of death are generally not available for NNTC cases. The results of the brain and CSF VL analyses on subsets of the current sample suggest that accelerated aging may be associated with greater viral replication. Larger samples will be needed to address this. Furthermore, noted by Jaffe and Irizarry (Jaffe and Irizarry 2014) . cellular composition may affect DNAm profiles within tissue. While we did not observe an association between age acceleration and various histological markers, the markers were quantified in several brain regions outside of the region used to derive the epigenomic data (occipital lobe), and only a subset of cell types were measured indirectly through these methods. Finally, we have used the term Baccelerated epigenetic agingf or the sake of consistency with previous articles (Horvath et al. 2015a, b; Horvath and Levine 2015) . however, the term Bpremature aging^may be more appropriate since our limited sample size did not allow us to assess whether there is an actual increase in the rate of change.
With an accurate method for determining biological age and accelerated aging in brain tissue, it is now possible to examine biological correlates and behavioral consequences of accelerated aging in the context of HIV. We previously found that HIV infection is associated with accelerated biological aging in the brains of infected individuals (Horvath and Levine 2015) . and here, we show that accelerated aging is also associated with HAND. Additional studies will aid in elucidating the direction of this association since our data do not lend themselves for addressing whether accelerated epigenetic aging causes HAND, or vice versa. We believe that applying this methodology to histopathological studies, where DNA methylation is assayed in adjacent regions to tissue undergoing histopathological characterization and/or HIV viral load assay, will further aid in the explication age-related neuropathogenesis due to HIV. Further, applying the epigenetic clock to the study of HANA pathogenesis in general may enable an accurate measure of age acceleration that can then be examined in association with relevant biological and clinical factors. One exciting possibility is that the changes in DNAm may play a role in the onset and progression of neurodegenerative diseases (Migliore and Coppede 2009 ). As such, targeting this epigenetic process with effective compounds opens a new area of preventative and therapeutic approaches for neuroHIV.
